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Background: Repetitive transcranial magnetic stimulation (rTMS) has shown promise in the alleviation of acute and
chronic pain by altering the activity of cortical areas involved in pain sensation. However, current single-coil rTMS
technology only allows for effects in surface cortical structures. The ability to affect activity in certain deep brain
structures may however, allow for a better efficacy, safety, and tolerability. This study used PET imaging to
determine whether a novel multi-coil rTMS would allow for preferential targeting of the dorsal anterior cingulate
cortex (dACC), an area always activated with pain, and to provide preliminary evidence as to whether this targeted
approach would allow for efficacious, safe, and tolerable analgesia both in a volunteer/acute pain model as well as
in fibromyalgia chronic pain patients.
Methods: Part 1: Different coil configurations were tested in a placebo-controlled crossover design in volunteers
(N = 16). Tonic pain was induced using a capsaicin/thermal pain model and functional brain imaging was performed
by means of H2
15O positron emission tomography – computed tomography (PET/CT) scans. Differences in NRS pain
ratings between TMS and sham treatment (NRSTMS-NRSplacebo) which were recorded each minute during the
10 minute PET scans. Part 2: 16 fibromyalgia patients were subjected to 20 multi-coil rTMS treatments over 4 weeks
and effects on standard pain scales (Brief Pain Inventory, item 5, i.e. average pain NRS over the last 24 hours) were
recorded.
Results: A single 30 minute session using one of 3 tested rTMS coil configurations operated at 1 Hz consistently
produced robust reduction (mean 70% on NRS scale) in evoked pain in volunteers. In fibromyalgia patients, the 20
rTMS sessions also produced a significant pain inhibition (43% reduction in NRS pain over last 24 hours), but only when
operated at 10 Hz. This degree of pain control was maintained for at least 4 weeks after the final session.
Conclusion: Multi-coil rTMS may be a safe and effective treatment option for acute as well as for chronic pain, such as
that accompanying fibromyalgia. Further studies are necessary to optimize configurations and settings as well as to
elucidate the mechanisms that lead to the long-lasting pain control produced by these treatments.
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Repetitive transcranial magnetic stimulation (rTMS) uses
an electromagnetic coil placed over the scalp to induce
electrical current pulses within conductive brain tissue
in order to modulate the endogenous activity of this
tissue. One limitation of current rTMS technology is
that deeper brain structures, known to be involved in
pain perception, are difficult to target because magnetic
field pulse strength rapidly drops as a function of distance
from the coil into the brain, and beyond 2–3 cm from the
scalp there is insufficient power from a single coil to
produce action potentials [1]. Attempts to reach deeper
into the brain by increasing power delivered to the coil
is not a viable solution, as this approach leads to scalp
pain from activation of cutaneous afferents, as well as
a relative overstimulation of superficial brain areas,
accompanied by risks of off-target effects and seizures.
Therefore, most studies trying to utilize rTMS as a
treatment for acute or chronic pain have stimulated
relatively superficial parts of the brain such as primary
motor cortex (M1) [2-6] or the dorsolateral prefrontal
cortex [4]. Other groups have used enlarged coil diameters
[5-7] in an attempt to reach structures deep within the
brain. While enabling the delivery of greater energy levels
to depth, this is accomplished at the expense of focality
[8] and is thus accompanied by a greater risk of off-target
adverse effects [8].
In this study, we used a new approach to specifically
target a deeply located brain structure, i.e. the dorsal an-
terior cingulate cortex (dACC), which plays an important
role in both cognitive and affective pain perception [9] as
demonstrated by fMRI [10] and PET [11] functional im-
aging studies. In addition to being implicated in acute and
chronic pain perception, morphometric magnetic reson-
ance imaging has shown decreases in the dACC in pa-
tients with chronic pain conditions, such as fibromyalgia
[10,12]. In addition, changes in fractional anisotropy in the
dACC as detected by diffusion tensor imaging have been
shown with chronic pain conditions as well [13]. Also,
real-time fMRI feedback control of the dACC seems to be
an evolving method for pain modulation [14].
A novel multi-coil rTMS device (Cervel Neurotech,
Foster City, CA) simultaneously activating up to 4 single
electromagnetic coils was used to tailor magnetic field
pulses towards having the maximal effect on the dACC.
We tested the effects of three different coil rotational
configurations on acute pain in healthy volunteers using
an acute, 10 minute duration thermal pain/capsaicin
sensitization model as well as on chronic pain and
depression in fibromyalgia patients. Finite element analysis
simulations of PET data recorded immediately after each
treatment in volunteers was also conducted so as to gain
insight into the spatial distribution of the magnitude and
direction of energy delivered by each treatment at specificcoil power levels used in each individual subject. The
coil configuration found to produce the most consistent
analgesia in this volunteer study was then used to determine
whether similar magnetic stimulation parameters would
alleviate chronic pain in fibromyalgia patients.
Results
Pain assessment in volunteers
Differences in pain ratings after real and placebo treat-
ment while in the PET scanner are shown in Figure 1
Configuration B produced a significant, robust analgesic
effect (AUC −30.5 ± 1.7). For configuration A no clear
analgesic or hyperalgesic effect could be observed (AUC
2.6 ± 15.7). Mean area under the curve was significantly
lower with configuration B compared configurations A and
C indicating a significant analgesic effect for configuration
B. Interestingly, configuration C appeared to produce a
moderate hyperalgesic effect (AUC 9.5 ± 4.9), potentially
indicating an enhancement of pro-algesic structures.
When calculating the activity ratios for average PET
activity in the deep (posterior dorsal ACC, anterior
dorsal ACC, and the pregenual ACC) versus superficial
(supplementary motor area (SMA), preSMA, dorsomedial
PFC, and rostromedial PFC) regions of interest in each
volunteer, configuration B lead to the biggest decrease in
PET activity ratio changes (Figure 2). Consistent with this
finding is the observation of the significant analgesic effect
after real multi-coil rTMS with configuration B. Interest-
ingly, these changes in PET activity ratio were mostly
explained by the almost absent change in activation in the
superficial brain areas, -0.04 and 0.125 for configuration A
and B, respectively. This indicates that the multi-coil
rTMS causes its effect by modulating deep rather than
superficial brain structures. Correlating the PET activity
ratio with the averaged change in NRS pain ratings during
the first 2 minutes (the time period over which H2
15O
PET is most sensitive due to the rapid decay) yielded a
significant correlation coefficient of 0.61.
Pain assessment in fibromyalgia patients
Analysis of variance indicated that BPI item 5 was signifi-
cantly affected by configuration (F(3,5) = 14.42, p < 0.0001)
and time point (F(3,5) = 3.83, p = 0.004). There was no
significant interaction between configuration and time
point. The post hoc Bonferroni comparisons showed that
compared to the 4 coil 1 Hz real TMS configuration both
10 Hz configurations had significant effects on BPI item
5 at PT4 time point - 4 weeks after the final treatment
(Figure 3). Both configurations B and E, applied at 10 Hz
showed a progressive analgesic effect that developed over
the 4 week time course of treatment sessions. In addition,
the pain scores for these two configurations remained
significantly attenuated 4 weeks after the final treatment
session. BPI item 5 ratings 4 weeks after the last treatment
NRS time course volunteers






























Figure 1 Time course of numerical pain ratings (rTMS-sham) for each configuration. The inset shows the averaged area under the curve
(AUC ± SEM). *, #: p < 0.05 for configuration B vs. configuration A and configuration C, respectively (one-way ANOVA).
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(both operated at 10 Hz), respectively, compared to the
pre-treatment baseline ratings. The 4 coil 1 Hz real TMS
treatment group did not significantly differ from the 4 coil
1 Hz sham TMS treatment group (15% decrease for both
configurations compared to baseline).
For the secondary outcome measures, analysis of vari-
ance revealed a significant effect of time point for changes
in Fibromyalgia Impact Questionnaire (FIQ, F(3,3) = 3.74,






























Figure 2 Ratio of deep vs. superficial PET ROI activity changes
(real treatment – sham treatment). Configurations A and B lead
to a marked decrease, whereas configuration C lead to a small
increase in activity ratio. *: indicated p < 0.05 (one way ANOVA).significant. Two-way analysis of variance of the Beck
Depression Inventory data revealed no significant effects
for time point, configuration, and interaction, respectively.
No significant changes in between groups were detected
in the post hoc Bonferroni comparisons for both FIQ and
BDI-II (Table 1).
Adverse events
No serious adverse events were observed in either the
volunteer portion nor in the fibromyalgia patients portion
of this study. Adverse events with relatively high incidences
(more than 10% of patients, sham vs. real) included scalp
pain (11 vs. 2%, p = 0.03), headache (78 vs. 75%, ns),
lightheadedness (22 vs. 2%, p < 0.001), back pain (11 vs.
8%, ns), neck pain (0 vs. 13%, p < 0.001), otalgia (11 vs.
4%, ns), nausea (11 vs. 19%, ns), hot flashes (22 vs. 0%,
p < 0.001), and pruritus (22 vs. 7%, ns). Interestingly,
some of these adverse events (lightheadedness, hot flashes,
and scalp pain) occurred with the highest incidence rates
in the 4 coil 1 Hz sham rTMS group. Neck pain occurred
significantly more often in patients that received real
rTMS treatment. There was no significant difference in
adverse event rates for occipital pressure (0 vs. 2%, ns),
ocular discomfort (0 vs 2%, ns), or vomiting (0 vs 2%, ns)
between sham and real rTMS treatment.
Discussion
This study sought to investigate the analgesic effects of
using a multi-coil rTMS array to preferentially target a
structure located deeply in the brain, namely the dACC.
We used an acute pain model in volunteers to perform
BPI item5
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Figure 3 Time course of BPI item 5 ratings (average pain in the
last 24 hours) in fibromyalgia patients for the investigated
configurations. T1, T10, T20: day of 1st, 10th, and 20th treatment
session, respectively. PT1 and PT4: 72 hours and 4 weeks after the
last treatment.*: p < 0.05 vs. 4coil 1 Hz real (2-way ANOVA with post
hoc Bonferroni analysis).
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single TMS session on capsaicin-induced thermal hyper-
algesia and to establish an optimal coil configuration.
The second part of the study exposed fibromyalgia patients
to this optimal configuration over 20 treatment sessions,
assaying the effects of these treatments on these patients’
pain. In addition, this study examined changes in BDI and
FIQ in these patients as secondary outcome measures.
Volunteer study
Configuration B, one of the three investigated configur-
ation in the volunteer part of the study, yielded robust
analgesic effects, whereas configuration C was, if any-
thing, hyperalgesia inducing. The effect of configuration
A was highly variable across subjects, with some vo-
lunteers demonstrating analgesia, some hyperalgesia,Table 1 Fibromyalgia impact questionnaire (FIQ) and the
beck depression inventory (BDI-II) ratings over the course
of and after the treatments (average ± SD)
FIQ 4 coil 1Hz real 4 coil 1Hz sham 4coil 10 Hz 2 coil 10 Hz
T1 65.8 ± 8.1 72.9 ± 12.0 68.7 ± 14.9 60.7 ± 14.4
T10 67.6 ± 10.9 64.5 ± 14.3 47.4 ± 21.4 52.0 ± 21.6
PT1 56.0 ± 15.9 54.3 ± 18.5 41.8 ± 15.2 51.4 ± 21.9
PT4 65.3 ± 6.2 50.1 ± 19.1 37.8 ± 15.8 41.2 ± 9.3
BDI-II 4 coil 1Hz real 4 coil 1Hz sham 4coil 10 Hz 2 coil 10 Hz
T1 10.3 ± 13.1 22.2 ± 12.2 12.6 ± 7.4 18.3 ± 11.3
PT1 9.7 ± 11.2 15.8 ± 10.0 8.0 ± 6.3 15.0 ± 11.9
PT4 14.0 ± 13.1 10.8 ± 7.6 4.6 ± 5.7 9.5 ± 6.4
T1 and T10: timepoint of 1st and 10th treatment, respectively. PT1: 72 hours
after last treatment. PT4: 4 weeks after last treatment. Two-way analysis of
variance showed that there was a significant effect of time point for FIQ
(F(3,3) = 3.74, p = 0.017). There was no significant effect of configuration and
no significant effect of interaction between configuration and time point for
FIQ. Two-way analysis of variance for the BDI-II data showed no significant
effect of configuration, time point, or interaction.some no effect – thus, for this configuration demon-
strated no average effect. This observation might be due
to the relatively small size of the targeted brain structure
compared with the area of brain influenced by multi-coil
rTMS and the vicinity of multiple other critical pain
processing centers. Future studies are warranted to in-
vestigate the effects of distinct settings of multi-coil
rTMS on target structures.
The ratios for deep versus superficial activation were
large for configurations A and B. Interestingly, although
one would expect to obtain relatively high activation
results close to the magnetic coils, the large ratios were
mostly explained by the almost absent change in activation
of the medial prefrontal cortex, the brain region closest to
one of the 4 coils that was usually stimulating with the
highest power setting (“top” coil). One possible explanation
for the relatively small activation change in the mPFC is
that because it may not be primarily activated, but in fact
deactivated with the nociceptive input used [15] – unlike
the dACC – the region may have been at a resting state or
even deactivated during the pain stimulus. Thus and it is
possible that the 1 Hz rTMS used is more effective in
modulating resting/deactivated cortex rather than affecting
an activated state.
Effect of rTMS settings – configuration and stimulation
frequency
The 1 Hz pulse frequency that showed analgesic effect
in the acute pain/volunteer study was not effective for
the treatment of chronic pain in fibromyalgia patients.
This might be explained by a relatively short-termed
effect induced by this stimulation frequency. In volunteers,
the acute analgesic effect appeared to last only about
6 minutes on average (Figure 4). The hyperalgesic effect
observed after TMS with configuration C showed a
similar decrease over time. Those effects are most likely
not due to habituation, since similar trends were not
observed for configuration A. Another factor that may
explain the lack of effect of the 1Hz setting in the fibro-
myalgia patient population is the difference in age of
subjects. In fact, the oldest volunteer was younger than
the youngest fibromyalgia patient. Specific configurations
might be necessary to obtain desired changes in brain
plasticity depending on the age of treated subjects. Future
studies should be performed to evaluate effects of age-
specific rTMS configurations. A final explanation might
be related to morphometric, and presumably cytoarchitec-
tonic structural differences between the dACC of normal
volunteers and those of fibromyalgia patients [12]. It may
be that the smaller restructured dACC of fibromyalgia
patients may be inherently less susceptible to low frequency
pulses. Perhaps the most significant finding from these
studies is the persistence of analgesic effects for at least
4 weeks after the final treatment session. This effect
Figure 4 Three coil configurations used in the PET imaging
study are displayed over standard EEG10-20 coil positions.
Large circles represent the coils, and the arrows within represent the
direction of the primary electrical current within that coil at the
point of contact with the scalp. Note that all configurations have the
same four geometric centers for each coil, but the coils are variously
rotated so as to shape the magnitude and direction of the resulting
magnetic field. The diagram is a planar representation of the curved
head surface such that F3, F4 (lateral) and Fpz (anterior) positions
are actually approximately vertical and at 90 degrees from the most
posterior (“top” coil).
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neuroplastic processes. It will be critical, in future studies,
to determine whether and to what extent these events are
recognizable in structural and/or functional scans of
similarly treated patients, e.g. reversal of the previously
observed morphological differences in the dACC of
fibromyalgia patients.
Extent of analgesic effect
Short et al. [16] tested the effects of left prefrontal cortex
rTMS on pain in fibromyalgia patients and observed a
significant mean 29% reduction of pain ratings in the
real TMS group as compared to a non-significant mean
4% reduction in the sham TMS group. We observed a
31% and 56% reduction of pain ratings for configuration
B (10Hz) and configuration E, respectively, at the 4 weeks
post treatment compared to 15% for both 4 coil 1 Hz
and sham treatment. A possible explanation for this
increased analgesic effect compared to the results of Short
et al. could be that the shaped magnetic field pulses used
in our study were capable of differentially targeting
neuronal structures that are more critical in the neuronal
pain circuitry (prefrontal cortex vs. dACC) – something
that cannot be done using a single coil. However, Short
et al. performed only ten rTMS sessions as opposed to 20
sessions in our study and the part of the enhanced
analgesic effect could thus also be contributed to the
increase in sessions.
For the secondary outcome measures changes in BDI
and FIQ, we observed a general trend for FIQ to improve
with time, independent of configuration used. It may
be that because our patient population started from a
relatively low level on both scores, the lack of significancefor the BDI-II may be due to a floor effect. It is interesting
to note that this general trend of improved FIQ scores
seemed to be independent of improvement in pain ratings,
i.e. FIQ severity were not directly linked to extent of
pain experienced from fibromyalgia. The general trend
to improve in the FIQ could also be explained by an
increase in patient care while enrolled in the study. An
important implication of these results is that, since there
was no correlation between improvement in depression
and analgesia, it is highly unlikely that the analgesic effects
observed were secondary to a treatment-induced anti-
depressive effect.
Appropriate sham rTMS
An inherent problem of rTMS is choosing an ideal sham
intervention. Simply placing the magnetic coil over a
different brain area or at a different angle might still lead
to cortical activation or inhibition and could thus have
an effect on the observed outcome parameters [17]. Pre-
senting the characteristic clicking sounds from a recorded
audio file as also used in our study may not be an ideal
sham procedure since there is no tactile scalp stimulation.
However, since multiple coil configurations were used in
the volunteer study, with only one consistently producing
analgesia, the other configuration/stimulation sets might
serve as excellent additional controls. In each case, scalp
and auditory sensations would be very similar or identical
to those sensed with configuration B. Similarly, despite
being effective for acute pain in volunteers, the 4 coil 1 Hz
rTMS configuration did not produce a significant analgesic
effect in the chronic pain population, but still generated
similar sensory cues. In addition, it has been suggested that
assessment of duration of analgesic effect might be a better
way to discriminate between placebo analgesia and a real
treatment effect. In a study performed by Price et al. [18]
either saline or a local anesthetic was injected into sympa-
thetic ganglia to alleviate pain from Complex Regional
Pain Syndrome (CRPS). While there was no significant
difference between peak analgesic effects, the duration of
analgesic effect was significantly longer after injection
of local anesthetics compared to saline. Transferring
these findings to our study, a placebo effect 4 weeks
after the final rTMS treatment session seems extremely
improbable.
Potential mechanisms
It was not the primary aim of this study to reveal potential
mechanisms of neural responses to magnetic brain
stimulation, however we would like to summarize
some potential mechanisms of transcranial magnetic
stimulation. One should keep in mind that although
generally maximum magnetic field intensity is considered
to be the most important factor, other factors such as
induced electrical fields, spatial summation, potential
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dependent thresholds may play an important role in
mediating rTMS effects. Further studies are warranted
to understand the distinct roles that these mechanisms
may have in order to optimize future rTMS research
and treatment protocols.
The results provided here indicate that multi-coil
shaped field rTMS directed toward the dACC might
provide a safe and effective means of alleviating both
acute and chronic pain. Distinct configurations are re-
quired to achieve effects depending on type of pain and/
or patient age and possible other factors that still need
to be determined. The capacity to differentially target
specific structures deep within the brain may suggest
numerous additional applications for this relatively new
but fast evolving treatment approach of rTMS.
Conclusions
Multi-coil repetitive transcranial magnetic stimulation was
successfully used to reliably and safely affect the dorsal
anterior cingulate cortex, a deep brain structures that is
critical to pain perception, but which cannot be selectively
reached with single-coil approaches. Particular configura-
tions and frequencies of field pulses directed toward the
dorsal anterior cingulate cortex reduced acute pain in volun-
teers and chronic pain in fibromyalgia patients. In addition,
the effect on fibromyalgia pain was persistent for at least
4 weeks following treatment, indicating the induction of a




After obtaining informed consent, 16 volunteers were
enrolled for the first stage of this study. The average age
for the volunteers was 24.8 ± 5.4 years (range 18–38), 5
male and 11 female. Exclusion criteria for the volunteer
study were: pregnancy, seizure disorder, use of medica-
tions that have the potential of substantially lowering
seizure threshold, cardiac pacemaker, electrically conductive
implants in the brain, increased intracerebral pressure,
minority age, allergy to capsaicin, claustrophobia, actively
manifest Axis I psychiatric disorder as assessed though
the MINI neuropsychiatric interview by a board-certified
psychiatrist, inability to give informed consent, use of
analgesics within the previous 2 weeks, acute or chronic
pain, and previous experience with TMS. The study
enrolling volunteers was approved by the Committee on
Human Research, University of California, San Francisco,
where the study was conducted.
Pain induction and assessment in volunteers
On the scanning day, baseline warmth sensation threshold,
heat-pain threshold (HPTpre) and maximum heat tolerancetemperature (HTTpre) were determined for each volunteer
using a Peltier thermode (Medoc Ltd, Israel). In order to
train volunteers in rating their pain with an 11-point
numerical rating scale (0 to 10, NRS), the temperature of
the thermode was then set to random temperatures for
5 s between the individual HPTpre and HTTpre separated
by 30-s intervals, and the volunteers were asked to rate
their pain. To allow for a moderate to strong pain over a
10 minute period while being in the PET/CT scanner
without producing skin damage, we then sensitized the skin
of the forearm to heat with capsaicin cream (Capsaicin-hp
0.075%, Clay-Parks Lab.) covered with an occlusive dressing.
After 20 min, the dressing and remaining capsaicin cream
were removed using an alcohol swab and subjects were
re-tested for pain threshold (HPTpost) and tolerance
(HTTpost) and asked to rate their pain as described above.
For both PET scans after placebo and TMS, the
temperature of the thermode was set to HPTpost plus 60%
of HTTpost-HPTpost. During each 10 minute PET scan,
tonic pain was evoked by strapping the Peltier onto the
capsaicin-treated skin and maintaining the thermode at
this temperature. To assess for effects of rTMS and
sham treatments, volunteers were asked to rate their
Peltier-evoked pain once per minute during each PET scan.TMS device, procedure and configurations
Each subject’s resting motor threshold (MT) was deter-
mined by TMS stimulation over the site of the motor
cortex, with a positive response in the motor cortex
indicated by the minimum power level that produced
movement of the subject’s contralateral thumb. To insure
subject comfort, maximal TMS power was set to be 110%
of motor threshold. However, the subjects’ comfort was
assessed throughout the stimulation – if, at any time the
patient indicated significant discomfort from the stimulus,
the power was decreased incrementally. Simultaneous
stimuli produced by pulsed (1 Hz) magnetic fields gener-
ated by the four coils produced a composite field the
shape of which is dependent on the placement of the four
coils on the head as well as the polarity of the fields. The
center of each of the coils was at least 4 cm from the
center of each other coil, thereby insuring that superficial
magnetic fields did not summate above the power of any
one coil. The coil configurations tested, A, B and C,
shown in Figure 5, were generated using mathematical
modeling of the composite field generated by simultaneous
activation of 4 coils. Each stimulation session was carried
out for a period of 30 minutes and consisted of 1800 pulses.
For the sham procedure, the four coils were placed on
the subject’s head in an identical manner to that used in
the “real” stimulus session. Thereafter, an audio recording
of the characteristic TMS clicking sound was played from
speaker mounted behind the top of the subject’s head at a
Figure 5 Representative PET scan images of one subject during noxious heat pain stimulation after sham (left side of the panel) and
real (ride side of the panel) multi-coil rTMS treatment. The red arrow indicates the ACC region. After sham treatment activity in the ACC
region seems to be increased by the noxious heat pain stimulus. After real multi-coil rTMS this activation was not observed.
Tzabazis et al. Molecular Pain 2013, 9:33 Page 7 of 9
http://www.molecularpain.com/content/9/1/33volume comparable with the real treatment and played for
30 minutes.
In order to minimize possible bias, the investigator,
who asked the volunteers for the pain rating was not
involved in operating the TMS device and the TMS oper-
ator was not involved in the volunteers’ pain assessment
for studying treatment effects. TMS operator did, however,
in each case, ask subjects about possible unpleasantness/
scalp pain induced by the TMS treatment.
As TMS produces very loud clicks, all subjects wore
ear plugs at all times while receiving real and sham
treatments to prevent ear damage.H2
15O PET scan
After obtaining intravenous access, subjects were trans-
ferred to the scanner (GE Discovery 64 slice PET/CT),
which was approximately 1 meter from the rTMS chair.
There the subjects laid supine, head first, arms down.
After advancing their head into the scanner, subjects
were instructed to remain still, while a scout scan or
topogram was acquired to determine the field of view
(~16.2 cm) for the CT and PET, respectively. After prep-
aration by a near-by cyclotron, a 10 mCi dose of H2
15O
in a small volume of normal saline (1–2 ml) was intra-
venously administered and flushed with 10 ml of normal
saline. Immediately after, a single bed image of the brain
was acquired for 10 minutes in dynamic mode. H2
15O was
produced in the in-house cyclotron installed at the China
Basin facilities of UCSF following human administration
standards and after RDRC approval. Due to the short
half-life (t1/2) of
15O (122 seconds), a brain PET scan canbe performed several times in a single experimental
session with the patient being in different pain states
(baseline, pain with sham treatment, and pain with real
treatment). Data were normalized, and appropriate cor-
rections were applied for dead time, randoms, scatter,
and attenuation.
Volume of interest and finite element analysis
Using computerized finite-element analysis (FEA), software
(Opera 3D, Cobham Technical Services, Oxfordshire,
England, U.K.) simulations were conducted for each specific
coil configuration, and the power levels received by each
individual subject in the acute and FMS pain studies. The
peak magnetic field spatial profile was then computed for
a series of volumes of interest in the brain that was corre-
lated with the analgesic effect produced by specific coil
configurations. From this matrix, values representing peak
magnetic field magnitude and direction were extracted
from locations corresponding with the dorsolateral
aspect of the prefrontal cortex (dLPFC), the dorsal anterior
cingulate cortex (dACC), and the cortical surface. Chan-
ging the x, y and z directional profiles illustrated the
steerability of the field pulses at depth and the unique
magnetic field shape created by each coil configuration.




Sixteen patients were included in the fibromyalgia study.
Ages for the patients ranged from 40–64 years (mean
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fibromyalgia diagnosis according to the American College
of Rheumatology criteria, moderate to severe pain (defined
as Brief Pain Inventory – BPI - item 5 rated as 4 or
greater) from fibromyalgia despite current and stable
treatment regimen, agreement not to become pregnant
during the study. Exclusion criteria were seizure disorder,
metal implants on or in the brain, spinal cord, ear, eye
or heart, current use of potentially proconvulsant medi-
cations, medication of oral amitriptyline > 100 mg/day,
non-scheduled (PRN) analgesics, anticonvulsant or anti-
depressant medications, use of opioid analgesics during
study participation, severe depression or suicidality,
other significant psychiatric disorder, and previous ex-
perience with TMS. The fibromyalgia patient study was
approved by Shulman Associates IRB (ClinicalTrials.gov
identifier: NCT01229852).
Assessment in fibromyalgia patients
Fibromyalgia patients were assessed using the Brief Pain
Inventory (BPI) questionnaire, the Fibromyalgia Impact
Questionnaire (FIQ) [19] and the Beck Depression Inventory
(BDI-II) [20].
The primary outcome measure in fibromyalgia patients
was change in item 5 of BPI, i. es average pain rating in
the last 24 hours, at the post-treatment time point 4
(4 weeks after last treatment session).
Secondary outcome measures included changes in FIQ
and BDI-II from the baseline.
TMS procedure and configuration in fibromyalgia patients
Determination of motor threshold and safety precautions
were performed as described for the volunteer study.
The “B” coil configuration used with most fibromyalgia
patients was that found to be most effective in the
volunteer study component – but applied at different
either 1 or 10 Hz, rather than all at the1 Hz frequency
used in the volunteers. Thus, the following configurations
were tested in fibromyalgia patients: 1) configuration B,
1 Hz, 2) sham configuration B, 1 Hz, 3) configuration B,
10Hz. In addition, a 2 coil, 10 Hz configuration designated
“E” was designed to mimic the field shape produced by
configuration B, but with less specificity.
Patients received 20 daily treatment sessions of 30 minutes
each over a 4 week period.
Statistical analysis
All data are presented as average ± SEM.
For the volunteer study, differences in NRS ratings of
volunteers (NRSreal, min1 – NRSsham, min1, etc.) were calcu-
lated for each minute while subjects were in the PET
scanner. To minimize the problem of multiple comparisons,the area under the curve (AUC) was calculated for each





tiþ1−tið Þ yi þ yiþ1
 
where yi represents the difference in NRS ratings (real
TMS – sham TMS) reported at times ti (i = 0,…,n) [21].
AUCs for pain NRS were then averaged according to
configuration and tested with one-way ANOVA with post
hoc Bonferroni comparisons for significant differences.
For the imaging data, three deep and four superficial
regions of interest (ROI) were defined: (1) deep ROI:
posterior dorsal ACC, anterior dorsal ACC, and the
pregenual ACC (2) superficial ROI: supplementary
motor area (SMA), preSMA, dorsomedial PFC, and
rostromedial PFC [22]. Activity changes (rTMS treat-
ment – placebo treatment) were averaged for the deep
and superficial ROIs, respectively, and a ratio of deep
versus superficial average change was calculated for
each of the investigated coil configurations. The Pearson
product–moment correlation coefficient was calculated
for PET activity change ratios and changes in pain per-
ception as measured by NRS ratings during the first
2 minutes of the H2
15O PET scan accounting for the
short half-life of 15O.
For the fibromyalgia study, data was analyzed using a
repeated measures two-way ANOVA with Bonferroni
post hoc comparisons for the primary and secondary
outcome measures.
Incidences of treatment-related adverse events were
tested for significance using chi2 test with Yates’ correction.
For this analysis, data for all real rTMS groups (4coil 1Hz,
4coil 10Hz, and 2coil 10Hz) was pooled and compared to
the 4coil 1Hz sham treatment group.
The significance level for all statistical tests was set
to p < 0.05.
Competing interests
AT has in the past functioned as paid consultant to Cervel Neurotech Inc.
and owns stock options.
CMA has no competing interests.
MCR has in the past functioned as paid consultant to Cervel Neurotech Inc.
MBS is founder and Chief Medical Officer, employee of Cervel Neurotech Inc.
He owns stock in the company and has intellectual property rights.
AE has no competing interests.
DCY has in the past functioned as paid consultant to Cervel Neurotech Inc.
and owns stock.
Authors’ contributions
AT helped in designing the study, carried out psychophysical testing,
analyzed data and drafted the manuscript. CMA carried out PET/CT
imaging and helped in drafting the manuscript. MCR helped in designing
the study and drafting the manuscript. MBS helped in designing the
study, performed TMS treatments, analyzed data and helped in drafting
the manuscript. AE analyzed data and helped in drafting the manuscript.
DCY designed the study, carried out psychophysical testing, analyzed
data and helped in drafting the manuscript. All authors read and
approved the final manuscript.
Tzabazis et al. Molecular Pain 2013, 9:33 Page 9 of 9
http://www.molecularpain.com/content/9/1/33Disclosures
Some of this work has been shown in the form of a poster presented at the
Society of Biological Psychiatry meeting 2012, and the poster is now publicly
viewable at http://f1000.com/posters/browse/summary/1090251.
The device used in the research described in this publication is not yet
commercially available and is limited by Federal (United States) law to
investigational use.
Author details
1Department of Anesthesiology, Pain, and Perioperative Medicine, Stanford
University School of Medicine, Stanford, CA, USA. 2Department of Radiology,
University of California San Francisco, San Francisco, CA, USA. 3Sierra-Pacific
Mental Illness Research Education and Clinical Center, Veterans Affairs Palo
Alto Health Care System, Palo Alto, CA, USA. 4Cervel Neurotech Inc, Foster
City, CA, USA. 5Department of Psychiatry and Behavioral Sciences, Stanford
University School of Medicine, Stanford, CA, USA. 6Department of
Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
7California Pacific Medical Center Research Institute, San Francisco, CA, USA.
Received: 8 April 2013 Accepted: 29 June 2013
Published: 2 July 2013
References
1. Epstein CM, Zangaladze A: Magnetic coil suppression of extrafoveal visual
perception using disappearance targets. J Clin Neurophysiol : official
publication of the American Electroencephalographic Society 1996, 13:242–
246.
2. André-Obadia N, Peyron R, Mertens P, Mauguière F, Laurent B, Garcia-Larrea
L: Transcranial magnetic stimulation for pain control. Double-blind study
of different frequencies against placebo, and correlation with motor
cortex stimulation efficacy. Clin Neurophysiol 2006, 117:1536–1544.
3. Hirayama A, Saitoh Y, Kishima H, Shimokawa T, Oshino S, Hirata M, Kato A,
Yoshimine T: Reduction of intractable deafferentation pain by navigation-
guided repetitive transcranial magnetic stimulation of the primary motor
cortex. Pain 2006, 122:22–27.
4. Borckardt JJ, Smith AR, Reeves ST, Madan A, Shelley N, Branham R, Nahas Z,
George MS: A pilot study investigating the effects of fast left prefrontal
rTMS on chronic neuropathic pain. Pain medicine (Malden, Mass) 2009,
10:840–849.
5. Zangen A, Hyodo K: Transcranial magnetic stimulation induces increases
in extracellular levels of dopamine and glutamate in the nucleus
accumbens. Neuroreport 2002, 13:2401–2405.
6. Epstein CM, Davey KR: Iron-core coils for transcranial magnetic
stimulation. J Clin Neurophysiol : official publication of the American
Electroencephalographic Society 2002, 19:376–381.
7. Roth Y, Amir A, Levkovitz Y, Zangen A: Three-dimensional distribution of
the electric field induced in the brain by transcranial magnetic
stimulation using figure-8 and deep H-coils. J Clin Neurophysiol : official
publication of the American Electroencephalographic Society 2007, 24:31–38.
8. Deng Z-D, Lisanby SH, Peterchev AV: Electric field depth-focality tradeoff
in transcranial magnetic stimulation: Simulation comparison of 50 coil
designs. Brain Stimul 2013, 6:1–13.
9. Eisenberger NI: The pain of social disconnection: examining the shared
neural underpinnings of physical and social pain. Nat Rev Neurosci 2012,
13:421–34.
10. Freund W, Klug R, Weber F, Stuber G, Schmitz B, Wunderlich AP: Perception
and suppression of thermally induced pain: a fMRI study. Somatosens
Mot Res 2009, 26:1–10.
11. Lieberman MD, Jarcho JM, Berman S, Naliboff BD, Suyenobu BY, Mandelkern
M, Mayer EA: The neural correlates of placebo effects: a disruption
account. Neuroimage 2004, 22:447–55.
12. Burgmer M, Gaubitz M, Konrad C, Wrenger M, Hilgart S, Heuft G, Pfleiderer
B: Decreased gray matter volumes in the cingulo-frontal cortex and the
amygdala in patients with fibromyalgia. Psychosom Med 2009, 71:566–73.
13. Lutz J, Jäger L, De Quervain D, Krauseneck T, Padberg F, Wichnalek M, Beyer
A, Stahl R, Zirngibl B, Morhard D, Reiser M, Schelling G: White and gray
matter abnormalities in the brain of patients with fibromyalgia: a
diffusion-tensor and volumetric imaging study. Arthritis Rheum 2008,
58:3960–9.
14. Chapin H, Bagarinao E, Mackey S: Real-time fMRI applied to pain
management. Neurosci Lett 2012, 520:174–81.15. Guangchen J, Neugebauer V: Pain-related deactivation of medial
prefrontal cortical neurons involves mGluR1 and GABA(A) receptors. J
Neurophysiol 2011, 106:2642–52.
16. Short EB, Borckardt JJ, Anderson BS, Frohman H, Beam W, Reeves ST,
George MS: Ten sessions of adjunctive left prefrontal rTMS significantly
reduces fibromyalgia pain: a randomized, controlled pilot study. Pain
2011, 152:2477–84.
17. Loo CK, Taylor JL, Gandevia SC, McDarmont BN, Mitchell PB, Sachdev PS:
Transcranial magnetic stimulation (TMS) in controlled treatment studies:
are some “sham” forms active? Biol Psychiatry 2000, 47:325–31.
18. Price DD, Long S, Wilsey B, Rafii A: Analysis of peak magnitude and
duration of analgesia produced by local anesthetics injected into
sympathetic ganglia of complex regional pain syndrome patients. Clin J
Pain 1998, 14:216–26.
19. Burckhardt CS, Clark SR, Bennett RM: The fibromyalgia impact
questionnaire: development and validation. J Rheumatol 1991, 18:728–33.
20. Beck AT, Steer RA, Ball R, Ranieri W: Comparison of Beck Depression
Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996,
67:588–97.
21. Matthews JN, Altman DG, Campbell MJ, Royston P: Analysis of serial
measurements in medical research. BMJ (Clinical research ed) 1990,
300:230–5.
22. Etkin A, Egner T, Kalisch R: Emotional processing in anterior cingulate and
medial prefrontal cortex. Trends Cogn Sci 2011, 15:85–93.
doi:10.1186/1744-8069-9-33
Cite this article as: Tzabazis et al.: Shaped magnetic field pulses by multi-
coil repetitive transcranial magnetic stimulation (rTMS) differentially
modulate anterior cingulate cortex responses and pain in volunteers and
fibromyalgia patients. Molecular Pain 2013 9:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
